Core Insights - Quantum BioPharma Ltd. has submitted its patented drug candidate Lucid-21-302 (Lucid-MS) for the Innovative Licensing and Access Pathway (ILAP) Passport program in the UK, aiming to provide a new treatment for multiple sclerosis (MS) [1][3] Group 1: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with drug candidates at various development stages [4] - The company’s lead compound, Lucid-MS, is a patented new chemical entity that has shown potential in preventing and reversing myelin degradation in preclinical models [4] - Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and has a royalty agreement that includes 7% of sales until total payments reach $250 million, after which the royalty will drop to 3% [4] Group 2: ILAP Passport Program - The ILAP Passport is designed to expedite the development and delivery of groundbreaking medicines by fostering collaboration among medicine developers, regulatory bodies, and the NHS [2] - The program aims to streamline the process of developing, reviewing, approving, and delivering new treatments to patients, ensuring timely access to medical innovations [2] Group 3: Statements from Company Executives - Dr. Andrzej Chruscinski expressed excitement about the ILAP Passport submission, highlighting its potential to accelerate clinical development and patient access to Lucid-21-302 [3] - Dr. Lakshmi P. Kotra emphasized the company's commitment to bringing innovative drugs to patients quickly and the importance of global regulatory strategies [4]
Quantum BioPharma Submits its Candidate Breakthrough Patented Drug for Multiple Sclerosis for Fast-Track Program in the United Kingdom